Amarin (AMRN) Receives Additional Patent Allowance for Vascepa
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/16/2026
- Wall St ends higher on cool inflation data, strong earnings
- U.S. headline producer inflation posts first one-month decrease since August 2025
- PayPal rallies 20% on report Stripe, Advent made $53 billion bid
- Oil prices make small gain on smaller US inventory draw
- ASML capacity upgrade soothes AI chip bottleneck fears
Amarin (AMRN) Vascepa Growth Continues; Sees Limited Negative Read-Through from Merck's HPS2-THRIVE
March 11, 2013 10:54 AM EDTMKM Partners commented on Amarin Corporation (NASDAQ: AMRN) Monday as Vascepa prescription continue to gain momentum although sales might fall below the consensus.
The firm notes that after eight weeks, Vascepa total weekly prescriptions increased to 1,017 for the week ending March 1 from 838 the week prior (up 21% week over week). Analyst Jon LeCroy said current growth continues, assuming a wholesale cost of $184 per prescription and a prescription under-reporting rate of 22%, that would... More
